Determination of Buspirone HCl in Commercial Dosage Forms by Extractive Spectrophotometric Method and Comparison by HPLC Method

Abstract

An extractive spectrophotometric method has been developed for the determination of buspirone HCl in tablets. It was based on the ion-pair complex formation between buspirone and bromothymol blue in presence of disodium hydrogen phosphate and citric acid buffer solution of pH 4.0 which is extractable in chloroform. The extracted complex showed maximum absorbance at 412 nm. Beer's law was obeyed in the concentration range of 1.25-30 µg ml-1. Various factors affecting the reaction conditions were carefully studied and optimized. Validation parameters based on the guidelines of International Conference on Harmonisation, USA were followed. Effect of common excipients used as additives has been tested and the tolerance limit was calculated for the determination of buspirone HCl. Limits of detection and quantitation were 0.165 and 0.499 µg ml-1 , respectively. Proposed method has been successfully applied for the determination of buspirone HCl in pharmaceutical formulations. High performance liquid chromatographic method was employed using 250 mm × 4.6 mm i.d., 5-µm particle, reversed phase C18 column with 70:30 (v/v) methanol-0.01M NaH 2 PO 4 buffer as a mobile phase at a flow rate of 0.8 ml min-1 and UV detection at 240 nm for best separation of buspirone. Results obtained by the proposed method were statistically compared with the HPLC reference method using t-and F-values and found no significant difference between the two methods. The proposed method can be used as an alternate method for routine quality control analysis of buspirone HCl in pharmaceutical formulations.

Two-layer Electrospun System Enabling Wound Exudate Management and Visual Infection Response

“…Figure 6 presents the ATR-FTIR spectra of pure BTB raw material, electrospun PAA, thermally-crosslinked electrospun PAA, electrospun PMMA-co-MAA and core-shell fibres CS-PAA12-(PMMA-co-MAA). The FTIR spectrum of raw BTB exhibits bands at 1346 cm −1 , 1162 cm −1 and 1042 cm −1 , which are assigned to the –SO 3 functional group and the asymmetric and symmetric S-O-C stretching vibration bands at 880 cm −1 and 796 cm −1 [92,93]. A band at 651 cm −1 due to C–Br stretching vibrations is also detected [94].…”

Halochromic Polystyrene Nanofibers Obtained by Solution Blow Spinning for Wine pH Sensing

“…In the pure BTB spectrum, the characteristic bands were identified in regions near 1190 cm −1 and 1026 cm −1 , corresponding to vibrations of the −SO 3 group [50]. The bands at 891 and 794 cm −1 were associated with symmetric and asymmetric S−O−C stretching, respectively [51]. A low-intensity band associated with the C−S stretching vibration was observed at 716 cm −1 [52].…”

“…In the pure BTB spectrum, the characteristic bands were identified in regions near 1190 cm −1 and 1026 cm −1 , corresponding to vibrations of the −SO3 group [50]. The bands at 891 and 794 cm −1 were associated with symmetric and asymmetric S−O−C stretching, respectively [51]. A low-intensity band The pure PS polymer spectrum (not shown) did not differ from the spectrum of the PS nanofiber in the absence of BTB, indicating that the blow spinning process for fiber formation did not affect the polymer structure.…”

Development and in Vitro Assessment of Buspirone Loaded in Situ Nanoemulsion Gel

“…This is because the nasal route offers a direct link between brain and nose resulting in reduced drug concentration at the non-target site (which reduces the drug toxicity) and higher drug concentration in the brain [1,2] thus improving therapeutic efficiency which overcomes the limitation of conventional drug delivery systems Buspirone [8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro (4,5)decane-7,9-dione] is an approved anxiolytic agent belonging to the chemical class of azaspirodecanedione and is available as a tablet (Buspar®, Anxiron®, Anxut®, Bespar®) used for generalized anxiety disorder (GAD), relieve symptoms of anxiety and for unipolar depression [3]. This dosage form exhibit low bioavailability (approximately 5%) due to extensive first-pass metabolism and nontargeted delivery results in numerous side effects, such as dizziness, drowsiness, headache, nausea, nervousness, lightheadedness, restlessness, blurred vision, tiredness, and trouble sleeping may occur [4].…”